Summary by Futu AI
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into...Show More